Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial

Michael C Reade, Kim O'Sullivan, Samantha Bates, Donna Goldsmith, William R S T J Ainslie, Rinaldo Bellomo, Michael C Reade, Kim O'Sullivan, Samantha Bates, Donna Goldsmith, William R S T J Ainslie, Rinaldo Bellomo

Abstract

Introduction: Agitated delirium is common in patients undergoing mechanical ventilation, and is often treated with haloperidol despite concerns about safety and efficacy. Use of conventional sedatives to control agitation can preclude extubation. Dexmedetomidine, a novel sedative and anxiolytic agent, may have particular utility in these patients. We sought to compare the efficacy of haloperidol and dexmedetomidine in facilitating extubation.

Methods: We conducted a randomised, open-label, parallel-groups pilot trial in the medical and surgical intensive care unit of a university hospital. Twenty patients undergoing mechanical ventilation in whom extubation was not possible solely because of agitated delirium were randomised to receive an infusion of either haloperidol 0.5 to 2 mg/hour or dexmedetomidine 0.2 to 0.7 microg/kg/hr, with or without loading doses of 2.5 mg haloperidol or 1 mug/kg dexmedetomidine, according to clinician preference.

Results: Dexmedetomidine significantly shortened median time to extubation from 42.5 (IQR 23.2 to 117.8) to 19.9 (IQR 7.3 to 24) hours (P = 0.016). Dexmedetomidine significantly decreased ICU length of stay, from 6.5 (IQR 4 to 9) to 1.5 (IQR 1 to 3) days (P = 0.004) after study drug commencement. Of patients who required ongoing propofol sedation, the proportion of time propofol was required was halved in those who received dexmedetomidine (79.5% (95% CI 61.8 to 97.2%) vs. 41.2% (95% CI 0 to 88.1%) of the time intubated; P = 0.05). No patients were reintubated; three receiving haloperidol could not be successfully extubated and underwent tracheostomy. One patient prematurely discontinued haloperidol due to QTc interval prolongation.

Conclusions: In this preliminary pilot study, we found dexmedetomidine a promising agent for the treatment of ICU-associated delirious agitation, and we suggest this warrants further testing in a definitive double-blind multi-centre trial.

Trial registration: Clinicaltrials.gov NCT00505804.

Figures

Figure 1
Figure 1
[CONSORT patient flow diagram 44]. * Intervention was discontinued because of consultant physician concern at the length of the QTc interval.
Figure 2
Figure 2
Graph showing time to extubation.

References

    1. Fraser GL, Prato BS, Riker RR, Berthiaume D, Wilkins ML. Frequency, severity, and treatment of agitation in young versus elderly patients in the ICU. Pharmacotherapy. 2000;20:75–82. doi: 10.1592/phco.20.1.75.34663.
    1. Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE, Jr, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit.[see comment] JAMA. 2004;291:1753–62. doi: 10.1001/jama.291.14.1753.
    1. Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult.[see comment][erratum appears in Crit Care Med 2002 Mar;30(3):726] Critical Care Medicine. 2002;30:119–41. doi: 10.1097/00003246-200201000-00020.
    1. Riker RR, Picard JT, Fraser GL. Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients.[see comment] Critical Care Medicine. 1999;27:1325–9. doi: 10.1097/00003246-199907000-00022.
    1. Menza MA, Murray GB, Holmes VF, Rafuls WA. Decreased extrapyramidal symptoms with intravenous haloperidol. J Clin Psychiatry. 1987;48:278–280.
    1. Freeman BD, Dixon DJ, Coopersmith CM, Zehnbauer BA, Buchman TG. Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients. Pharmacoepidemiol Drug Saf. 2008;17:971–981. doi: 10.1002/pds.1637.
    1. MIMS Annual . St Leonards: MediMedia Australia Pty Limited; 2004.
    1. Hassaballa HA, Balk RA. Torsade de pointes associated with the administration of intravenous haloperidol:a review of the literature and practical guidelines for use. Expert Opin Drug Saf. 2003;2:543–547.
    1. Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drugs. 2000;59:263–268. doi: 10.2165/00003495-200059020-00012.
    1. Romero C, Bugedo G, Bruhn A, Mellado P, Hernandez G, Castillo L. Experiencia preliminar del tratamiento con dexmedetomidina del estado confusional e hiperadrenergia en la unidad de cuidados intensivos. Revista Espanola de Anestesiologia y Reanimacion. 2002;49:403–6.
    1. Pandharipande PP, Pun BT, Herr DL, Maze M, Girard TD, Miller RR, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007;298:2644–2653. doi: 10.1001/jama.298.22.2644.
    1. Ruokonen E, Parviainen I, Jakob SM, Nunes S, Kaukonen M, Shepherd ST, et al. Dexmedetomidine versus propofol/midazolam for long-term sedation during mechanical ventilation. Intensive Care Med. 2009;35:282–290. doi: 10.1007/s00134-008-1296-0.
    1. Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009;301:489–499. doi: 10.1001/jama.2009.56.
    1. Martin J, Anderson T, Turton C, Hart GK, Hicks P. Intensive care resources & activity: Australia and New Zealand 2003–2005. Melbourne: Australian and New Zealand Intensive Care Society; 2006.
    1. Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med. 2002;166:1338–1344. doi: 10.1164/rccm.2107138.
    1. Bergeron N, Dubois MJ, Dumont M, Dial S, Skrobik Y. Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med. 2001;27:859–864. doi: 10.1007/s001340100909.
    1. Bachand R, Scholz J, Pinaud M, Merli M, Zandstra D. The effects of dexmedetomidine in patients in the intensive care unit setting. Intensive Care Med. 1999;25(Suppl 1):S160. Ref Type: Abstract.
    1. Bachand RT, Werner L, Etropolski M. A phase III study evaluating dexmedetomidine for sedation in postoperative patients. Anesthesiology. 2008;91:296. Ref Type: Abstract.
    1. Mantz J, Goldfarb G, Lehot J-J, Ecoffey C. Dexmedetomidine efficacy for ICU postoperative sedation. Anesthesiology. 1999;91:197. Ref Type: Abstract.
    1. Martin E, Ramsay G, Mantz J, Sum-Ping ST. The role of the alpha2-adrenoceptor agonist dexmedetomidine in postsurgical sedation in the intensive care unit. J Intensive Care Med. 2003;18:29–41. doi: 10.1177/0885066602239122.
    1. Shehabi Y, Ruettimann U, Adamson H, Innes R, Ickeringill M. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med. 2004;30:2188–2196. doi: 10.1007/s00134-004-2417-z.
    1. Venn M, Newman J, Grounds M. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Medicine. 2003;29:201–7.
    1. Pandharipande P, Shintani A, Peterson J, Pun BT, Wilkinson GR, Dittus RS, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology. 2006;104:21–26. doi: 10.1097/00000542-200601000-00005.
    1. Wunsch H, Meltzer JS. Sedation with dexmedetomidine vs lorazepam in mechanically ventilated patients. JAMA. 2008;299:1540–1541. doi: 10.1001/jama.299.13.1540-b.
    1. Dotson B, Peeters MJ. Sedation with dexmedetomidine vs lorazepam in mechanically ventilated patients. JAMA. 2008;299:1540. doi: 10.1001/jama.299.13.1540-a.
    1. Barletta JF, Devlin JW. Sedation with dexmedetomidine vs lorazepam in mechanically ventilated patients. JAMA. 2008;299:1541–1542. doi: 10.1001/jama.299.13.1541.
    1. Riker R, Shehabi Y, Pencina M, Bokesch P, Bradt J. The cost effectiveness of dexmedetomidine vs. midazolam in adult ICU patients with prolonged mechanical ventilation: an economic model. Crit Care Med. 2008;36(12):A17. Ref Type: Abstract.
    1. Seitz DP, Gill SS, van Zyl LT. Antipsychotics in the treatment of delirium: a systematic review. J Clin Psychiatry. 2007;68:11–21.
    1. Han CS, Kim YK. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics. 2004;45:297–301.
    1. Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Medicine. 2004;30:444–9. doi: 10.1007/s00134-003-2117-0.
    1. Riker RR, Fraser GL, Cox PM. Continuous infusion of haloperidol controls agitation in critically ill patients.[see comment] Critical Care Medicine. 1994;22:433–40. doi: 10.1097/00003246-199403000-00013.
    1. Seneff MG, Mathews RA. Use of haloperidol infusions to control delirium in critically ill adults. Ann Pharmacother. 1995;29:690–693.
    1. Venn RM, Bradshaw CJ, Spencer R, Brealey D, Caudwell E, Naughton C, et al. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia. 1999;54:1136–1142. doi: 10.1046/j.1365-2044.1999.01114.x.
    1. Ickeringill M, Shehabi Y, Adamson H, Ruettimann U. Dexmedetomidine infusion without loading dose in surgical patients requiring mechanical ventilation: haemodynamic effects and efficacy. Anaesth Intensive Care. 2004;32:741–745.
    1. Devlin JW, Fong JJ, Howard EP, Skrobik Y, McCoy N, Yasuda C, et al. Assessment of delirium in the intensive care unit: nursing practices and perceptions. Am J Crit Care. 2008;17:555–565.
    1. Van Eijk MM, Kesecioglu J, Slooter AJ. Intensive care delirium monitoring and standardised treatment: a complete survey of Dutch Intensive Care Units. Intensive Crit Care Nurs. 2008;24:218–221. doi: 10.1016/j.iccn.2008.04.005.
    1. Page VJ, Navarange S, Gama S, McAuley DF. Routine delirium monitoring in a UK critical care unit. Crit Care. 2009;13:R16. doi: 10.1186/cc7714.
    1. Pandharipande P, Cotton BA, Shintani A, Thompson J, Pun BT, Morris JA, Jr, et al. Prevalence and risk factors for development of delirium in surgical and trauma intensive care unit patients. J Trauma. 2008;65:34–41. doi: 10.1097/TA.0b013e31814b2c4d.
    1. Pandharipande P, Cotton BA, Shintani A, Thompson J, Costabile S, Truman PB, et al. Motoric subtypes of delirium in mechanically ventilated surgical and trauma intensive care unit patients. Intensive Care Med. 2007;33:1726–1731. doi: 10.1007/s00134-007-0687-y.
    1. Darrouj J, Puri N, Prince E, Lomonaco A, Spevetz A, Gerber DR. Dexmedetomidine infusion as adjunctive therapy to benzodiazepines for acute alcohol withdrawal. Ann Pharmacother. 2008;42:1703–1705. doi: 10.1345/aph.1K678.
    1. Maccioli GA. Dexmedetomidine to facilitate drug withdrawal. Anesthesiology. 2003;98:575–577. doi: 10.1097/00000542-200302000-00041.
    1. Ouimet S, Riker R, Bergeron N, Cossette M, Kavanagh B, Skrobik Y. Subsyndromal delirium in the ICU: evidence for a disease spectrum. Intensive Care Med. 2007;33:1007–1013. doi: 10.1007/s00134-007-0618-y.
    1. Ely EW, Inouye SK, Bernard GR, Gordon S, Francis J, May L, et al. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU) JAMA. 2001;286:2703–2710. doi: 10.1001/jama.286.21.2703.
    1. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663–694.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner